May 20, 2025
JAKARTA – An ongoing clinical trial for a tuberculosis (TB) vaccine candidate in Indonesia has been met with rising public criticism, especially on social media, which experts attribute to unclear communication from health authorities surrounding the program.
Indonesia was selected as one of the countries to host the third phase of clinical trials for TB vaccine candidate M72/AS01E to assess the efficacy of the substance developed by London-based pharmaceutical company GlaxoSmithKline (GSK). The vaccine’s development is supported by the Bill & Melinda Gates Foundation, which was cofounded by American philanthropist and Microsoft cofounder Bill Gates and his wife at…